Engineered t cells take on Hard-to-Treat cancers in new trial

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer cells, combined with a drug called decitabine. The goal is to find a safe dose and see if the treatment can shrink tumors or slow disease progression.